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Abstract
We report the ﬁrst detection of blaCTX-M-19 in South America,
harboured in an Escherichia coli isolate obtained from a urine
sample; such an isolate belonged to phylogenetic group A, ST603,
and showed a ceftazidimase proﬁle. blaCTX-M-19 was encoded in an
approximately 100 kb IncI1/IncF conjugative plasmid, featuring
pndAC and hok/sok addiction systems; the b-lactamase gene was
ﬂanked upstream by three tandem-like transposons (IS26, IS10
and ISEcp1), inserted one inside the other, and downstream by
IS903.
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Worldwide dissemination of CTX-M-derived extended spec-
trum b-lactamases (ESBLs) is a well-known concern [1].
Although this process probably began simultaneously at the
beginning of the 1990s in Europe and South America [2],
differences in antibiotic pressure forces resulted in different
evolutionary routes. Thus, while CTX-M-9, CTX-M-14 and
CTX-M-15 were frequently detected in Europe [1],
CTX-M-2 was predominant in many countries of South
America [3–5].
Nevertheless, this situation has been gradually changing, and
the arrival of CTX-M-2 in Europe [1] was accompanied by the
progressive detection of CTX-M-9, CTX-M-14 and CTX-M-15
in our continent [3–7]. However, so far, the ceftazidimase
CTX-M-19 has only been reported in Europe [8].
In December 2010, Escherichia coli strain EC1737 was
isolated from a urine sample from a 10-year-old girl admitted
to the paediatric hospital Centro Hospitalario Pereira Rossell
(CHPR) of Montevideo, Uruguay.
Identiﬁcation and antibiotic susceptibility proﬁle were
determined using the VITEK 2 Compact system (bioMerieux,
Marcy l’Etoile, France). Minimal inhibitory concentration values
for ciproﬂoxacin, cefotaxime, ceftazidime, gentamicin, and
amikacin were determined by E-test; results were interpreted
according to EUCAST guidelines (http://www.eucast.org).
Strain EC1737 displayed a ceftazidimase-like proﬁle, being
resistant to gentamicin, nalidixic acid, ciproﬂoxacin, nitrofur-
antoin and trimethoprim–sulfamethoxazole; nevertheless,
EC1737 remained susceptible to amikacin, imipenem and
meropenem (Table 1).
The genes blaCTX-M, blaSHV, blaTEM and blaPER-2 were sought
by polymerase chain reaction (PCR) and sequencing [5–7],
conﬁrming the presence of blaCTX-M-19 and blaTEM-1, respec-
tively.
In order to identify other mechanisms responsible for the
observed resistance proﬁle, we used PCR and sequencing to
study the presence of (a) class-1 and 2 integrons [5, 9], (b) sul1,
2 and 3 genes, (c) plasmid-mediated quinolone-resistance
genes (qnrABCDS, aac(6′)Ib-cr and qepA), and (d) mutations in
the quinolone-resistance determining region (QRDR) [10].
In this sense, strain EC1737 harboured sul1 and sul2 genes
and a class-1 integron with a 1500 bp variable region featuring
a dfr17-aadA5 array. These genes usually determine resistance
to trimethoprim–sulfamethoxazole, streptomycin and specti-
nomycin.
No plasmid-mediated quinolone resistance genes were
detected. Nevertheless, the analysis of the QRDR showed
two modiﬁcations in gyrA (Ser83Leu and Asp87Asn) and one in
parC (Glu84Lys), compared to wild-type alleles in E. coli K-12
(GenBank accession NP_416734 and NP_417491, respec-
tively). These mutations have previously been highlighted as
responsible for resistance to ciproﬂoxacin [11, 12].
The probable association of blaCTX-M-19 to insertion
sequences such as ISEcp1, IS26, IS903, ISCR1 was sought by
PCR and sequencing [6]. In this regard, blaCTX-M-19 was ﬂanked
by IS26 and IS903 (upstream and downstream, respectively).
IS26 and blaCTX-M-19 were separated by an 819 bp segment;
interestingly, this segment was formed by 544 bp correspond-
ing to a truncated IS10 insertion sequence and another 275 bp
belonging to a fragment of ISEcp1, a genetic element
commonly found upstream from blaCTX-M-14 alleles [13]
(Fig. 1).
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Conjugation assays were carried out using E. coli J53-2
(rifampin resistant, non-motile and ornithine negative) as
recipient; transconjugants were selected on MacConkey agar
supplemented with rifampin (150 mg/L) and ceftriaxone (1 mg/
L), or gentamicin (4 mg/L) [6].
Two different sets of transconjugants were obtained
(Fig. 2): (a) ceftriaxone-selected transconjugants (TcEC1737-
CRO), displaying only a similar b-lactam resistance pattern as
the donor strain, and positive PCR results for blaCTX-M
(Table 1); and (b) gentamicin-selected transconjugants
(TcEC1737CN), showing resistance to b-lactams, aminoglyco-
sides, and trimethoprim–sulfamethoxazole, but remaining
susceptible to nitrofurantoin and quinolones. PCR results
were positive for blaCTX-M, blaTEM, intI1, qacEdelta-1, sul1 and
sul2, and conﬁrmed the transfer of a class-1 integron with a
1500 bp variable region.
The plasmid incompatibility group was determined by PCR
according to Carattoli et al. [14].
IncI1, IncF, IncFIA and IncFIB, were detected in EC1737 and
TcEC1737CN but only IncI1 and IncF were detected in
TcEC1737CRO.
Plasmid size was estimated, for the donor strain and
transconjugants, by treatment with S1 nuclease (Fermentas,
Life Sciences, Vilnius, Lithuania) followed by pulsed-ﬁeld gel
electrophoresis (PFGE) as described previously [15].
Both strain EC1737 and TcEC1737CN harboured two
plasmids of 100 kb and 110 kb, approximately, whereas
TcEC1737CRO only harboured a 100 kb plasmid (Fig. 2).
The presence of plasmid maintenance mechanisms (i.e.
addiction systems) in the donor strain and transconjugants
TcEC1737CRO and TcEC1737CN was sought by PCR, as
reported elsewhere [16]. Results were conﬁrmed by amplicon
sequencing.
EC1737 and TcEC1737CN showed the presence of pndAC,
vagCD, ccdAB, hok/sok and pemKI, whereas TcEC1737CRO
only showed the presence of pndAC and hok/sok systems.
TABLE 1. Antibiotic susceptibility proﬁle of Escherichia coli EC1737 and transconjugants TcEC1737CRO and TcEC1737CN
Antibiotic(s)
Minimum inhibitory concentration (mg/L)
EC1737 TcEC1737CRO TcEC1737CN E. coli J53-2
Ampicillin (≥32) (≥32) (≥32) (4)
Tazobactam piperacillin (≤4) (≤4) (≤4) (≤4)
Cephalothin (≥64) (≥64) (≥64) (8)
Ceftazidime 4 8 6 0.38
Cefotaxime 2 1 1 0.12
Cefepime (≥1) (≥1) (≥1) (≥1)
Meropenem 0.02 0.02 0.02 0.02
Imipenem 0.25 0.25 0.25 0.25
Amikacin 1 0.20 0.20 0.20
Gentamicin 32 0.06 6 0.06
Nalidixic acid (≥32) (4) (4) (4)
Ciproﬂoxacin 4 0.03 0.03 0.03
Trimethoprim–sulfamethoxazole (≥320) (≤20) (≥320) (≤20)
Values in parentheses were determined by the Vitek-2 system.
FIG. 1. Comparison of various genetic surroundings of similar blaCTX-M genes, and the one described in pEC1737. IRL, left inverted repeat; IRR,
right inverted repeat. Numbers in brackets indicate bibliographical references. Images are not drawn in scale.
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Genetic characterization of strain EC1737 was done by: (a)
determination of the phylogenetic group, according to Cler-
mont et al. [17]; (b) screening for virulence determinants,
according Johnson et al. [18]; and (c) multiple locus sequence
typing (MLST), following the guidelines described in http://mlst.
ucc.ie/mlst/dbs/Ecoli.
In this sense, EC1737 belongs to phylogenetic group A;
screening for pathogenicity genes only yielded positive
results for iutA, whereas MLST assay showed that this strain
belongs to sequence type 603 (ST603; allelic proﬁle, 6, 4, 4,
16, 43, 8, 6).
The occurrence of human isolates harbouring blaCTX-M-19
has been reported only once, namely from a faecal isolate of
Klebsiella pneumoniae from a hospitalized girl in France,
co-colonized by E. coli and K. pneumoniae harbouring
CTX-M-14 (a likely precursor of CTX-M-19) [8].
Although there is no description of the plasmid bearing
the blaCTX-M-19 allele, such a gene was found to be ﬂanked
by two full insertion sequences, namely ISEcp1B and IS903D
[13].
Interestingly, Ho et al. [19] and Kim et al. [20] have
described alternative surroundings for blaCTX-M-14, involving
the interruption of ISEcp1 by the insertion in different sites of
IS10 or IS26.
Contrary to previous reports regarding CTX-M-9-derived
genes, blaCTX-M-19 in pEC1737 was preceded by three
tandem-like transposons, which appear to have inserted one
inside the other; this reﬂects the plasticity of insertion
sequences to mobilize antibiotic resistance genes. Regardless
of the different events of insertion and deletion of the various
insertion sequences, the expression of blaCTX-M-19 seems to be
driven by the promoter sequence present in ISEcp1, previously
described by Poirel et al. [13].
Although E. coli EC1737 is not an ExPEC strain, this type of
microorganism could act as a reservoir or carrier of antibiotic
resistance genes, as suggested by the presence in this strain of
two transferable plasmids. Additionally, the presence of at
least two insertion sequences ﬂanking blaCTX-M-19 could
account for self-transfer events between different plasmids,
or even from plasmids to the bacterial chromosome.
The sequence of blaCTX-M-19 and its surrounding region was
deposited in the EMBL database (European Bioinformatics
Institute) under accession number HG000669.
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